VBI-Vaccines-Vertical-Logo.png
VBI Vaccines Announces Poster Presentation at the 7th International Congenital CMV Conference & 17th International CMV Workshop  
April 03, 2019 08:00 ET | VBI Vaccines, Inc.
CAMBRIDGE, Mass., April 03, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI-Vaccines-Vertical-Logo.png
VBI Vaccines Announces Positive Final Phase 1 Study Results of Preventative CMV Vaccine
May 10, 2018 07:30 ET | VBI Vaccines, Inc.
CMV neutralizing antibodies against fibroblast cell infection induced in 100% of subjects who received the highest doseSafe and well-tolerated at all doses with no safety signals observedConference...
VBI-Vaccines-Vertical-Logo.png
VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at SITC 2017
November 10, 2017 08:00 ET | VBI Vaccines, Inc.
New data confirms use of intradermal delivery of eVLPs may be a potent “off-the-shelf” immunotherapy vaccinePoster presentation at the Society for Immunotherapy of Cancer’s (SITC) 32nd Annual Meeting...